142 related articles for article (PubMed ID: 38230624)
1. Associations between lipid-lowering drugs and pregnancy and perinatal outcomes: a Mendelian randomization study.
Wang R; Zhao J; Li L; Huo Y
J Hypertens; 2024 Apr; 42(4):727-734. PubMed ID: 38230624
[TBL] [Abstract][Full Text] [Related]
2. Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.
Miao L; Miao T; Zhang Y; Hao J
BMC Cancer; 2024 May; 24(1):602. PubMed ID: 38760735
[TBL] [Abstract][Full Text] [Related]
3. Causal association between lipid-lowering drugs and cancers: A drug target Mendelian randomization study.
Ding W; Chen L; Xia J; Pei B; Song B; Li X
Medicine (Baltimore); 2024 May; 103(18):e38010. PubMed ID: 38701318
[TBL] [Abstract][Full Text] [Related]
4. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study.
Huang W; Xiao J; Ji J; Chen L
Elife; 2021 Dec; 10():. PubMed ID: 34866576
[TBL] [Abstract][Full Text] [Related]
5. Association between Lipid-Lowering Drugs and Traumatic Subdural Hemorrhage: A Mendelian Randomization Study.
Chen K; Li H; Chen Y; Huang H; Wei L
J Integr Neurosci; 2024 Apr; 23(4):76. PubMed ID: 38682216
[TBL] [Abstract][Full Text] [Related]
6. Estimating the effect of lipid-lowering agents on novel subtypes of adult-onset diabetes.
Ye J; Guo K; Li J; Li X; Zhou Z; Yang L
Diabetes Metab Res Rev; 2024 May; 40(4):e3793. PubMed ID: 38661109
[TBL] [Abstract][Full Text] [Related]
7. Can Lipid-Lowering Drugs Reduce the Risk of Cholelithiasis? A Mendelian Randomization Study.
Dong H; Chen R; Xu F; Cheng F
Clin Epidemiol; 2024; 16():131-141. PubMed ID: 38410417
[TBL] [Abstract][Full Text] [Related]
8. Association between lipid-lowering drugs and allergic diseases: A Mendelian randomization study.
Xu Y; Li Y
World Allergy Organ J; 2024 Apr; 17(4):100899. PubMed ID: 38623319
[TBL] [Abstract][Full Text] [Related]
9. Genetic Association of Lipid-Lowering Drugs with Aortic Aneurysms: A Mendelian Randomization Study.
Gao X; Luo W; Qu L; Yang M; Chen S; Lei L; Yan S; Liang H; Zhang X; Xiao M; Liao Y; Lee AP; Zhou Z; Chen J; Zhang Q; Wang Y; Xiu J
Eur J Prev Cardiol; 2024 Feb; ():. PubMed ID: 38302118
[TBL] [Abstract][Full Text] [Related]
10. LDL-c Lowering, Ischemic Stroke, and Small Vessel Disease Brain Imaging Biomarkers: A Mendelian Randomization Study.
Dib MJ; Zagkos L; Meena D; Burgess S; Chirinos JA; Gill D
Stroke; 2024 Jun; 55(6):1676-1679. PubMed ID: 38572634
[TBL] [Abstract][Full Text] [Related]
11. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study.
Liang Z; Zhao L; Lou Y; Liu S
QJM; 2023 Jun; 116(6):421-428. PubMed ID: 36964718
[TBL] [Abstract][Full Text] [Related]
12. Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study.
Tan Z; Hong J; Sun A; Ding M; Shen J
Front Endocrinol (Lausanne); 2023; 14():1301163. PubMed ID: 38107516
[TBL] [Abstract][Full Text] [Related]
13. Circulating lipids, lipid-lowering drug targets, and breast cancer risk: Comprehensive evidence from Mendelian randomization and summary data-based Mendelian randomization.
Zhang Z; Zhang D
Cancer Causes Control; 2024 Jun; 35(6):983-994. PubMed ID: 38430374
[TBL] [Abstract][Full Text] [Related]
14. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
[TBL] [Abstract][Full Text] [Related]
15. Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study.
Li Z; Tian M; Jia H; Li X; Liu Q; Zhou X; Li R; Dong H; Liu Y
Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):197-206. PubMed ID: 37688479
[TBL] [Abstract][Full Text] [Related]
16. Associations of Lipids and Lipid-Lowering Drugs with Risk of Vascular Dementia: A Mendelian Randomization Study.
Zhang X; Geng T; Li N; Wu L; Wang Y; Zheng D; Guo B; Wang B
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615727
[TBL] [Abstract][Full Text] [Related]
17. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.
Qiao L; Lv S; Meng K; Yang J
Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113
[TBL] [Abstract][Full Text] [Related]
18. Lipid-lowering drugs and inflammatory bowel disease's risk: a drug-target Mendelian randomization study.
Zhao J; Chen R; Luo M; Gong H; Li K; Zhao Q
Diabetol Metab Syndr; 2024 Jan; 16(1):12. PubMed ID: 38191425
[TBL] [Abstract][Full Text] [Related]
19. Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study.
Ma W; Chen H; Zhang Z; Xiong Y
PLoS One; 2024; 19(2):e0293960. PubMed ID: 38416763
[TBL] [Abstract][Full Text] [Related]
20. Lipids, lipid-modifying drug target genes and migraine: a Mendelian randomization study.
Bi Y; Zhu Y; Tang S; Huang Y
J Headache Pain; 2023 Aug; 24(1):112. PubMed ID: 37596566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
